Ratings by Citi (Eric Joseph)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/9/2026 | PTC Therapeutics | PTCT | Upgrade | Buy (Neutral) |
70.87 (78.98) |
11.44% | Details | |
| 5/18/2026 | Cytokinetics | CYTK | New Coverage | Buy (N/A) |
75.85 (78.78) |
3.86% | Details | |
| 5/18/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Buy (N/A) |
74.23 (74.12) |
-0.15% | Details | |
| 5/18/2026 | BridgeBio Pharma | BBIO | New Coverage | Neutral (N/A) |
66.13 (66.27) |
0.21% | Details | |
| 5/18/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Buy (N/A) |
51.81 (54.69) |
5.56% | Details | |
| 5/18/2026 | Ascendis Pharma | ASND | New Coverage | Buy (N/A) |
240.50 (230.83) |
-4.02% | Details | |
| 5/18/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
286.98 (278.09) |
-3.1% | Details |
